YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer

Oral Oncology

Volumn 50, Issue 9, 2014, Pages 832-839

  Jerhammar, Fredrik ^a   Johansson, Ann Charlotte ^a   Ceder, Rebecca ^b   Welander, Jenny ^a   Jansson, Agneta ^a   Grafström, Roland C ^b,c   Söderkvist, Peter ^c   Roberg, Karin ^a,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^d Department of Clinical Immunology and Transfusion Medicine   (Sweden)

Author keywords

Drug resistance; Gene copy number; Head and neck cancer; Predictive marker; SCCHN; Treatment response; YAP1

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; PHOSPHOPROTEIN; PRIMER DNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN YAP1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; GENE SILENCING; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ARTICLE; CANCER CELL LINE; CANCER PATIENT; CANCER RESISTANCE; CHROMOSOME 11Q; CHROMOSOME 5P; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; GENE PRODUCT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN CELL; HUMAN TISSUE; MULTIPLE CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, MONOCLONAL, HUMANIZED; BASE SEQUENCE; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84905898161     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.06.003     Document Type: Article

References (40)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. C.R. Leemans, B.J. Braakhuis, and R.H. Brakenhoff The molecular biology of head and neck cancer Nat Rev Cancer 11 2011 9 22
3. A. Argiris, M.V. Karamouzis, D. Raben, and R.L. Ferris Head and neck cancer Lancet 371 2008 1695 1709
4. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
5. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
6. B. Szabo, G.A. Nelhubel, A. Karpati, I. Kenessey, B. Jori, and C. Szekely et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas Oral Oncol 47 2011 487 496
7. L. Licitra, R. Mesia, F. Rivera, E. Remenar, R. Hitt, and J. Erfan et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study Ann Oncol 22 2011 1078 1087
8. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, and N.C. Tebbutt et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
9. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, and P. Saletti et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
10. U. Kasten-Pisula, J. Saker, W. Eicheler, M. Krause, A. Yaromina, and S. Meyer-Staeckling et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification Int J Radiat Oncol Biol Phys 80 2011 1181 1188
11. M.A. SheikhAli, M. Gunduz, H. Nagatsuka, E. Gunduz, B. Cengiz, and K. Fukushima et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma Cancer Sci 99 2008 1589 1594
12. N. Kondo, M. Tsukuda, T. Taguchi, K. Nakazaki, A. Sakakibara, and H. Takahashi et al. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities Cancer Sci 102 2011 1717 1723
13. C.L. Martin, S.C. Reshmi, T. Ried, W. Gottberg, J.W. Wilson, and J.K. Reddy et al. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature Oral Oncol 44 2008 369 382
14. S. Ambatipudi, M. Gerstung, R. Gowda, P. Pai, A.M. Borges, and A.A. Schaffer et al. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome PloS one 6 2011 e17250
15. A. Bhattacharya, R. Roy, A.M. Snijders, G. Hamilton, J. Paquette, and T. Tokuyasu et al. Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis Clin Cancer Res 17 2011 7024 7034
16. R. Grenman, T.E. Carey, K.D. McClatchey, J.G. Wagner, K. Pekkola-Heino, and D.R. Schwartz et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck Cancer 67 1991 2741 2747
17. A. Jedlinski, A. Ansell, A.C. Johansson, and K. Roberg EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines J Oral Pathol Med 42 2013 26 36
18. H. Hatakeyama, H. Cheng, P. Wirth, A. Counsell, S.R. Marcrom, and C.B. Wood et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma PloS one 5 2010 e12702
19. R.K. O'Donnell, M. Kupferman, S.J. Wei, S. Singhal, R. Weber, and B. O'Malley et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity Oncogene 24 2005 1244 1251
20. M. Lukk, M. Kapushesky, J. Nikkila, H. Parkinson, A. Goncalves, and W. Huber et al. A global map of human gene expression Nat Biotechnol 28 2010 322 324
21. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, and M. Kubista et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments Clin Chem 55 2009 611 622
22. C.M. Leutenegger, C.N. Mislin, B. Sigrist, M.U. Ehrengruber, R. Hofmann-Lehmann, and H. Lutz Quantitative real-time PCR for the measurement of feline cytokine mRNA Vet Immunol Immunopathol 71 1999 291 305
23. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
24. S. Wheeler, D.R. Siwak, R. Chai, C. LaValle, R.R. Seethala, and L. Wang et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma Clin Cancer Res 18 2012 2278 2289
25. A.M. Snijders, B.L. Schmidt, J. Fridlyand, N. Dekker, D. Pinkel, and R.C. Jordan et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma Oncogene 24 2005 4232 4242
26. E. Roman, L.A. Meza-Zepeda, S.H. Kresse, O. Myklebost, E.N. Vasstrand, and S.O. Ibrahim Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization Oncol Rep 20 2008 825 843
27. N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, and A. Sivachenko et al. The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
28. N.G. Kim, E. Koh, X. Chen, and B.M. Gumbiner E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components Proc Natl Acad Sci U S A 108 2011 11930 11935
29. Y. Touil, W. Igoudjil, M. Corvaisier, A.F. Dessein, J. Vandomme, and D. Monte et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis Clin Cancer Res 2013
30. J.M. Huang, I. Nagatomo, E. Suzuki, T. Mizuno, T. Kumagai, and A. Berezov et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14 Oncogene 32 2013 2220 2229
31. L.A. Fernandez, M. Squatrito, P. Northcott, A. Awan, E.C. Holland, and M.D. Taylor et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation Oncogene 31 2012 1923 1937
32. X. Huo, Q. Zhang, A.M. Liu, C. Tang, Y. Gong, and J. Bian et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma Oncol Rep 29 2013 840 846
33. I. Lian, J. Kim, H. Okazawa, J. Zhao, B. Zhao, and J. Yu et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation Genes Dev 24 2010 1106 1118
34. B.V. Reddy, and K.D. Irvine Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins Dev Cell 24 2013 459 471
35. R. Urtasun, M.U. Latasa, M.I. Demartis, S. Balzani, S. Goni, and O. Garcia-Irigoyen et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation Hepatology 54 2011 2149 2158
36. A. Dong, A. Gupta, R.K. Pai, M. Tun, and A.W. Lowe The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation J Biol Chem 286 2011 18301 18310
37. J. Zhang, J.Y. Ji, M. Yu, M. Overholtzer, G.A. Smolen, and R. Wang et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway Nat Cell Biol 11 2009 1444 1450
38. I. Tinhofer, K. Klinghammer, W. Weichert, M. Knodler, A. Stenzinger, and T. Gauler et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment Clin Cancer Res 17 2011 5197 5204
39. A. Komuro, M. Nagai, N.E. Navin, and M. Sudol WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus J Biol Chem 278 2003 33334 33341
40. J. Omerovic, E.M. Puggioni, S. Napoletano, V. Visco, R. Fraioli, and L. Frati et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level Exp Cell Res 294 2004 469 479